According to Bespak parent company Consort Medical, Bespak will construct a new dedicated facility at it’s King’s Lynn, UK site in order to meet production demands after signing a contract to manufacture a proprietary dry powder inhaler. The multi-year contract relates to a development project known as DEV610 for “a global pharma company whose details remain confidential at this time.” The DPI is expected to launch in 2015, and the company says that the value of the contract will depend on sales.
Consort Medical Chief Executive Jonathan Glenn commented, “We are delighted to have secured this major contract, which further leverages our operational and regulatory expertise in the production of high volume, premium quality drug delivery devices. This represents a further execution of our strategy for organic growth”
Read the Consort press release.
